Entry of R5X4 and X4 Human Immunodeficiency Virus Type 1 Strains Is Mediated by Negatively Charged and Tyrosine Residues in the Amino-Terminal Domain and the Second Extracellular Loop of CXCR4  by Kajumo, Francis et al.
Virology 271, 240–247 (2000)
doi:10.1006/viro.2000.0308, available online at http://www.idealibrary.com onRAPID COMMUNICATION
Entry of R5X4 and X4 Human Immunodeficiency Virus Type 1 Strains Is Mediated
by Negatively Charged and Tyrosine Residues in the Amino-Terminal Domain and
the Second Extracellular Loop of CXCR4
Francis Kajumo,* Daniah A. D. Thompson,* Yong Guo,† and Tatjana Dragic*,1
*Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461; and
†Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016
Received November 19, 1999; returned to author for revision February 10, 2000; accepted March 10, 2000
CXCR4 mediates the fusion and entry of X4 and R5X4 strains of human immunodeficiency virus type 1 (HIV-1). The residues
involved in CXCR4 coreceptor function have not all yet been identified, but tyrosine and negatively charged residues in the
amino-terminal domain of CCR5 were shown to be indispensable for gp120 binding and entry of R5 and R5X4 strains. We
therefore evaluated the role of such residues in CXCR4 coreceptor function by replacing tyrosines (Y), aspartic acids (D), and
glutamic acids (E) with alanines (A) and testing the ability of these mutants to mediate the entry of X4 and R5X4 HIV-1 isolates.
Our results show that viral entry depends on YDE-rich clusters in both the amino-terminus and the second extracellular loop
of CXCR4. Different viral isolates vary in their dependence on residues in one or the other domain. The determinants of
CXCR4 coreceptor function are, therefore, more diffuse and isolate-dependent than those of CCR5. © 2000 Academic Press
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tHuman immunodeficiency virus type 1 (HIV-1) enve-
lope glycoprotein gp120 consecutively interacts with
CD4 and a coreceptor to mediate fusion and entry into
target cells (3, 22). CCR5 is the coreceptor for R5 strains,
CXCR4 mediates the entry of X4 strains (1, 7, 9, 11, 12, 17),
and R5X4 strains use both coreceptors, though not al-
ways with the same efficiency (8, 11, 34). The variable
regions of gp120, notably V1/V2 and V3, are involved in
determining coreceptor usage (24). However, the core-
ceptor-binding site on gp120 also comprises residues
that are conserved among HIV-1 strains of different tro-
pism (20, 30, 38). We and others have demonstrated that
a cluster of amino-terminal (Nt) residues in CCR5, mostly
composed of tyrosine and negatively charged amino
acids, is essential for fusion and entry of R5 and R5X4
strains (10, 13, 15, 28). These residues are directly in-
volved in gp120 binding but it is not known with which
region of the envelope glycoprotein they interact. The
conformation of the CCR5 extracellular domains is also
important for efficient viral fusion and entry (2, 18, 19, 27,
31, 37).
The determinants of CXCR4 coreceptor function have not
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240been fully established. The notion that they are confined to
the Nt and ECL2 stems from early work done with core-
ceptor chimeras and deletion mutants (5, 23, 26, 29, 35). It
was shown for example that HIV-2ROD and HIV-1NDK re-
uire both the Nt and ECL2 for efficient fusion and entry,
hereas HIV-1LAI does not require the presence of the
CXCR4 Nt (5). Furthermore, several studies showed that
the anti-CXCR4 monoclonal antibody (MAb) 12G5, which
recognizes an epitope in ECL2, was capable of neutral-
izing the entry of only some HIV-1 and HIV-2 isolates and
that this occurs in a cell-specific manner (5, 23, 35). In a
recent report, several charged residues in the Nt and
extracellular loops 1 and 2 (ECL1 and ECL2) were found
to be involved in CXCR4-mediated viral entry (6).
Charged residues in ECL2 had previously been impli-
cated in CXCR4 coreceptor function (21, 26) although one
study found that residues in ECL2 other than the charged
residues are important for viral entry (36). Taken together
hese studies suggest that there may be more than one
nvelope glycoprotein-binding site on CXCR4 and that
ifferent viruses preferentially interact with different ex-
racellular regions of this coreceptor. This notion is sup-
orted by the observation that escape mutants to the
XCR4-specific ligands AMD3100 and SDF-1 can still
se this coreceptor (32, 33). In addition, CXCR4 may exist
n multiple conformational, oligomeric, or sulfated states
hat influence its interaction with HIV-1 and monoclonal
ntibodies (16).
Since part of the coreceptor-binding site on gp120 is
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241RAPID COMMUNICATIONcomposed of conserved residues we hypothesized that
the gp120-binding sites on CCR5 and CXCR4 would com-
prise similar motifs. Negatively charged aspartic acid (D)
and glutamic acid (E) residues and polar tyrosine (Y)
residues in the Nt of CCR5 are involved in its coreceptor
function, so we assessed whether such residues also
play a role in CXCR4-mediated viral fusion and entry.
Only the Nt and ECL2 of CXCR4 contain Y-, D-, and E-rich
clusters. We therefore made single and multiple alanine
substitutions in these two domains of the coreceptor
(Fig. 1) and studied their effect on the entry of three X4
and three R5X4 HIV-1 strains. We also assessed the role
of serine 23 (S23) and cysteine 28 (C28) in viral entry
since the corresponding residues in CCR5 were shown
to be important for coreceptor function.
Alanine substitutions were introduced using PCR-
based site-directed mutagenesis, as described previ-
ously (13, 18, 28) (Fig. 1). We tested the CXCR4 mutants
for their abilities to mediate the entry of different HIV-1
isolates into U87MG-CD4 cells. This is a human neuro-
nal cell line that does not express CCR5 or CXCR4 and is
not infectable by any of our test isolates (13, 18, 28).
Briefly, cells were lipofected with wild-type or mutant
CXCR4 genes, and then infected with 100–200 ng/ml p24
of NLluc1env2 viruses pseudotyped with envelope gly-
oproteins from HIV-1HxB2, HIV-1NDK, HIV-1B3, HIV-189.6,
IV-1DH123, or HIV-1Gun-1. All are clade B isolates with the
exception of HIV-1NDK, which is from clade D (14). HIV-1B3
is a primary X4 strain (8), whereas HIV-1HxB2 and HIV-1NDK
are clones of T-cell line-adapted (TCLA) isolates. HIV-189.6
is an R5X4 virus but in our pseudotype assay it uses
CXCR4 about 100-fold more efficiently than CCR5.
HIV-1DH123 and HIV-1Gun-1 are also R5X4 viruses but they
se both coreceptors with equal efficiency in our assay.
uciferase activities were measured in cell lysates 72 h
ostinfection as described previously (13, 18, 28). All
XCR4 molecules used in this study had a 9-residue
emagglutinin (HA)-tag as a carboxy-terminal extension
o allow detection by dot-blotting with anti-HA antibodies.
xpression levels of mutant and wild-type CXCR4 pro-
eins were determined in each experiment as described
FIG. 1. Mutagenesis of the predicted extracellular loops of CXCR4. Th
shown. Aspartic acid residues (D, white squares), glutamic acid residu
in combination with alanines by PCR-based site-directed mutagenesis.
region.reviously (13, 18, 28). Integrated density values (i.d.v.)
ere used to standardize luciferase activities. Expres-ion levels of all mutants were between approximately
0 and 120% of wild-type coreceptor expression (Ta-
le 1).
Few of the Nt point mutations had a significant effect
n the entry of X4 HIV-1 strains, hence we note only
hose that decreased CXCR4 coreceptor function with at
east one test isolate by approximately 2-fold or more.
he D20A mutation decreased the entry of all three X4
est isolates by about 50% (Fig. 2a) and that of HIV-189.6 by
70% (Fig. 2b). The E26A substitution lowered the entry of
HIV-1HxB2 and HIV-1B3 by approximately 80% (Fig. 2a) and
hat of HIV-189.6 by about 90% (Fig. 2b). Finally, the S23A
hange decreased only HIV-1HxB2 entry by about 60%. A
ore profound effect on the entry of R5X4 strains was
bserved for a number of amino-terminal mutations
Fig. 2b). The Y7A, D10A, Y12A, S23A, and E26A substi-
utions mediated from 2- to 20-fold less entry of HIV-1DH123
and HIV-1Gun-1 than wild-type CXCR4. Overall, entry of
HIV-1Gun-1 was the most sensitive to these substitutions,
ith Y7A, D10A, Y12A, and S23A decreasing its entry by
n order of magnitude or more. HIV-1Gun-1 entry also was
decreased by about 50% by the E15A and D22A substi-
tutions, whereas the E32A switch decreased HIV-1DH123
entry by about 50% (Fig. 2b). It is noteworthy that substi-
tution C28A had no effect on the entry of any of our test
isolates (Figs. 2a and 2b).
Most of the single alanine substitutions in ECL2 had
little or no effect on the entry of our test isolates (Fig. 3).
We note that the effect of the ECL2 point mutations on
viral entry was strain-specific and no consistent pattern
of residue usage could be associated with the X4 or
R5X4 phenotype. The entry of HIV-1HxB2 was not affected
y any of the ECL2 mutations, but the entry of HIV-1NDK,
HIV-189.6, and HIV-1Gun-1 was decreased approximately
wofold by the substitution D193A. Mutation D181A de-
reased the entry of HIV-1B3 by about 60% and that of
solates HIV-1DH123 and HIV-1Gun-1 by about 40%. Finally,
substitution D187A decreased the entry of HIV-189.6 by
only approximately 50%.
To test whether combinations of the different muta-
tions might have a more profound effect on HIV-1 entry,
o acid sequences of the four human CXCR4 extracellular domains are
lack squares) and tyrosines (Y, white circles) were modified singly or
was confirmed by sequencing both strands of the entire CXCR4 codinge amin
es (E, bwe introduced multiple alanine substitutions in the Nt
and ECL2 (Figs. 4–6). We were able to significantly impair
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formula: (mutant idv 4 wt idv) 3 100%. All values are means of three
independent experiments.
242 RAPID COMMUNICATIONthe entry of HIV-1DH123 and HIV-1Gun-1 when we combined
he Y7A, D10A, and Y12A substitutions into a single
utant coreceptor (Fig. 4). The triple substitution Y7A/
10A/Y12A was almost entirely inactive for the entry of
IV-1Gun-1 and mediated only about 5% of HIV-1DH123 entry
ompared to the wild-type coreceptor. The triple mutant
7A/D10A/E26A also mediated only about 5% of both
IV-1DH123 and HIV-1Gun-1 entry, compared to wild-type
XCR4. The triple mutant D20A/Y21A/D22A decreased
nly the entry of HIV-1Gun-1 by about 85%, but when the
E26A switch is added to this cluster, to make a quadruple
mutant, the entry of all isolates was diminished by 65 to
95%. Finally, the combination of substitutions Y7A/D10A/
Y12A/D20A/Y21A/D22A decreased the entry of all X4 and
R5X4 isolates to between 5 and 15% of wild-type CXCR4-
mediated entry. Entry of R5X4 isolates was the most
affected by this sextuple substitution.
Some of the double alanine mutations in ECL2 also
had a significant effect on HIV-1 entry (Fig. 5). The double
substitutions D182A/D193A and Y184A/D193A lowered
HIV-1NDK entry to 10% of that mediated by wild-type
CXCR4. The double substitution Y184A/D193A also de-
creased entry of HIV-1B3 by about 75%. The D187A/Y190A
substitution decreased the entry of all of our test iso-
lates, except for HIV-1NDK and HIV-1Gun-1, by 60 to 90%.
inally, the double substitution D182A/Y184A most af-
ected the entry of HIV-189.6, reducing it by about 60%.
urther combinations of these alanine substitutions re-
ulted in poor expression of the mutant coreceptor so
hey were not tested for their effect on viral entry.
Finally, we chose to combine the Nt clusters Y7A/
10A/Y12A and D20A/Y21A/D22A with the ECL2 doublet
187A/Y190A, since these three groups of substitutions
ost affected the entry of the majority of our HIV-1
solates (Fig. 6). The combination Y7A/D10A/Y12A/
187A/Y190A decreased the entry of all test isolates by
5 to 95%. Substitutions D20A/Y21A/D22A/D187A/Y190A
ecreased the entry of X4 isolates HIV-1HxB2 and HIV-1NDK
by about 50% and lowered the entry of all the other
isolates by approximately 90%. Finally, the octuple sub-
stitution Y7A/D10A/Y12A/D20A/Y21A/D22A/D187A/
Y190A decreased the entry of all test isolates by 10- to
100-fold. The entry of R5X4 isolates was more affected by
these multiple mutations than the entry of X4 isolates.
Our results support the concept that both the Nt and
ECL2 of CXCR4 play a role in coreceptor function. We
found that residues Y7, D10, Y12, D20, Y21, D22, S23, and
E26 in the Nt and D182, Y184, D187, Y190, and D193 in
ECL2 influenced HIV-1 entry, albeit to variable extents. A
recent report by Chabot et al. concluded, however, that
residues E14 and E15 in the Nt are important for the entry
of HIV-1LAV, HIV-1IIIB, HIV-1SF2, and HIV-189.6. In our hands,
alanine substitutions of these two residues had no sig-
nificant effect on the entry of any of our test isolates,TABLE 1
Expression Levels of CXCR4 Mutants
CXCR4 mutants % wt CXCR4 expression
Nt
E2 69 6 12
Y7 75 6 15
D10 110 6 21
Y12 98 6 20
E14 118 6 17
E15 71 6 15
D20 86 6 18
Y21 85 6 13
D22 97 6 12
S23 21 6 7
E26 76 6 20
C28 70 6 15
E31 55 6 8
E32 88 6 17
Y7/D10 67 6 7
D10/Y12 73 6 12
Y7/Y12 98 6 21
Y7/Y12/E26 80 6 13
Y7/D10/Y12 69 6 8
D20/Y21/D22 72 6 7
D20/Y21/D22/E26 74 6 12
Y7/D10/Y12/
D20/Y21/D22 63 6 10
ECL2
E179 101 6 19
D181 54 6 8
D182 50 6 6
Y184 78 6 12
D187 31 6 7
Y190 35 6 6
D193 82 6 11
D182/Y184 60 6 8
D182/D193 77 6 9
D184/D193 82 6 8
D187/Y190 83 6 14
Nt/ECL2
Y7/D10/Y12/
D187/Y190 93 6 16
D20/Y21/D22/
D187/Y190 77 6 14
Y7/D10/Y12/
D20/Y21/D22/
D187/Y190 46 6 9
Note. Expression levels of mutant and wild-type CXCR4 proteins
were determined in each experiment. Cells lipofected with the CXCR4
mutants were detergent-lysed and clarified lysates were diluted (1:1) in
1% sodium dodecyl sulfate, 1 mM dithiothreitol. An aliquot correspond-
ing to approximately 1 3 105 cells was loaded onto a Protran nitrocel-
ulose membrane (Schleicher & Schuell). Detection of CXCR4 expres-
ion was carried out with rabbit anti-HA-tag antibody diluted 1:103
(Berkeley Antibody Co.), followed by horseradish peroxidase (HRP)-
labeled goat anti-rabbit IgG, also diluted 1:103 (Amersham). HRP activity
was detected with ECL Western blotting reagents (Amersham) accord-
ing to the manufacturer’s instructions, and autoradiographs were
scanned with the IS-1000 Digital Imaging System (Alpha Innotech
Corp.). The expression level of each mutant, expressed as a percent-
age of wild-type CXCR4 expression, is calculated using the followingincluding some of those used by Chabot et al., except for
HIV-1Gun-1 (6). This group also found that residues D97 in
L
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243RAPID COMMUNICATIONECL1 and R188 in ECL2, which we did not study, play a
role in coreceptor function. We also did not show a role
for D182 in the entry of any of our test isolates. This
residue was reported to affect the entry of HIV-1LAI by
FIG. 2. HIV-1 coreceptor function of CXCR4 Nt mutants. U87MG-
substitutions in the Nt were infected with NLluc1env2 reporter viruses
NDK, B3, 89.6, DH123, and Gun-1 (see panel for corresponding bar p
postinfection and standardized for CXCR4 expression levels (in integra
as a percentage of wild-type coreceptor activity, is calculated using the
100%. All values are means of three independent experiments, eachaBrosse et al. (21). Finally, we did confirm the impor-
ance of D193 for HIV-1NDK entry, as reported by Brelot etal. (4). The discrepancies between our results and those
of Chabot et al. and LaBrosse et al. are probably due to
the usage of different isolates and assays to test the
CXCR4 mutants.
lls transiently expressing wild-type CXCR4 or CXCR4 with alanine
otyped with different X4 (a) or R5X4 (b) envelope glycoproteins: HxB2,
). Luciferase activity (in relative light units, r.l.u.) was measured 72 h
nsity values, i.d.v.). The coreceptor activity of each mutant, expressed
ng formula: [(mutant luc r.l.u. 4 wt luc r.l.u.) 3 (mutant i.d.v. 4 wt i.d.v.)]
rmed in quadruplicate.CD4 ce
pseud
atterns
ted deWe did not observe consistent patterns of CXCR4
amino acid usage by X4 and R5X4 isolates, taken as
s pseu
). See
g
244 RAPID COMMUNICATIONphenotypic groups. Broadly, double substitutions in ECL2
had more of an effect on the entry of X4 strains, whereas
double substitutions in the Nt had more of an effect on
FIG. 3. HIV-1 coreceptor function of CXCR4 ECL2 mutants. U87MG
substitutions in the ECL2 were infected with NLluc1env2 reporter viruse
B3, 89.6, DH123, and Gun-1 (see panel for corresponding bar patterns
FIG. 4. HIV-1 coreceptor function of CXCR4 Nt mutants containing mu
or CXCR4 with alanine substitutions in the Nt were infected with NLluc en
lycoproteins: HxB2, NDK, B3, 89.6, DH123, and Gun-1 (see panel for correspthe entry of R5X4 strains. In light of this, it is interesting
to note that HIV-189.6, an R5X4 strain with a preference for
CXCR4 usage, behaved more like an X4 strain. Also,
cells transiently expressing wild-type CXCR4 or CXCR4 with alanine
dotyped with different X4 or R5X4 envelope glycoproteins: HxB2, NDK,
legend to Fig. 2. for more details.
ubstitutions. U87MG-CD4 cells transiently expressing wild-type CXCR4
2-CD4ltiple s
1 v reporter viruses pseudotyped with different X4 or R5X4 envelope
onding bar patterns). See legend to Fig. 2 for more details.
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245RAPID COMMUNICATIONHIV-1B3, a primary X4 strain, did not distinguish itself by
ts residue usage from the TCLA X4 strains. When three
r more alanine substitutions were introduced in the Nt,
he entry of X4 isolates was also affected. In fact, de-
reasing the entry of X4 isolates by an order of magni-
ude required a total of eight substitutions: six in the Nt
nd two in ECL2. These eight substitutions decreased
he entry of the R5X4 test isolates by two orders of
agnitude. The residual coreceptor activity of this
XCR4 mutant may be accounted for by S23 and the
emaining Y, D, and E residues.
CCR5 coreceptor function also depends on tyrosine
nd negatively charged residues, which are involved in
CR5/gp120 binding (25, 37). We assume, therefore, that
he Y, D, and E residues important for CXCR4-mediated
iral entry are similarly implicated in gp120 binding. It is
lso likely that the CXCR4 Nt and ECL2 are spatially
roximal, as they are thought to be in CCR5 (25), with
oth domains contributing residues to the gp120-binding
ite. It should be noted, however, that not all acidic
esidues that play a role in CXCR4-mediated viral entry
ecessarily participate in noncovalent bond formation
etween the coreceptor and gp120. Recent evidence
uggests that the tyrosine-sulfation of the CCR5 Nt plays
role in viral entry and gp120 binding (16). Tyrosine
ulfation of CXCR4 was also demonstrated and is pre-
umably also involved in CXCR4 coreceptor function (16).
FIG. 5. HIV-1 coreceptor function of CXCR4 ECL2 mutants containing
double substitutions. U87MG-CD4 cells transiently expressing wild-
type CXCR4 or CXCR4 with alanine substitutions in the ECL2 were
infected with NLluc1env2 reporter viruses pseudotyped with different
4 or R5X4 envelope glycoproteins: HxB2, NDK, B3, 89.6, DH123, and
un-1 (see panel for corresponding bar patterns). See legend to Fig. 2
or more details.he tyrosine sulfatase recognition sequence comprises
yrosine residues flanked by acidic residues. Mutagene-is of certain D and E residues may therefore inhibit
yrosine sulfation of the coreceptors, resulting in the loss
f three negative charges, which may be important for
p120 binding and HIV-1 entry.
Different X4 and R5X4 envelope glycoproteins may
nteract with different components of the YDE-rich (or
(SO4)DE-rich) region of the CXCR4 surface, accounting for
he observation that the entry of all isolates does not
epend on the same set of residues. The observation
hat AMD3100- and SDF-1-resistant X4 isolates can con-
inue to use CXCR4 as a coreceptor supports the concept
f a large, diffuse surface capable of providing more than
ne docking site for gp120. It is notable, however, that all
hemokine receptors described to date have YDE-rich
egions in their extracellular domains, yet most do not
ediate HIV-1 entry, and others do so only poorly. Hence,
he features that set CCR5 and CXCR4 apart and make
hem the most efficient coreceptors remain to be identi-
ied. Perhaps it is the way that the different YDE motifs
re exhibited on the surfaces of these receptors or their
bility to interact with CD4, or each other, or other mol-
cules on the cell surface that ultimately renders them
fficient mediators of viral entry.
FIG. 6. HIV-1 coreceptor function of CXCR4 Nt/ECL2 mutants con-
taining multiple substitutions. U87MG-CD4 cells transiently expressing
wild-type CXCR4 or CXCR4 with alanine substitutions in the Nt and
ECL2 were infected with NLluc1env2 reporter viruses pseudotyped
with different X4 or R5X4 envelope glycoproteins: HxB2, NDK, B3, 89.6,
DH123, and Gun-1 (see panel for corresponding bar patterns). See
legend to Fig. 2 for more details.
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